{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:14:03Z","timestamp":1792512843972,"version":"4.5.0"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>The most common cause of persistent hypoglycemia in the neonatal period is hyperinsulinism. Severe, refractory hypoglycemia resulting from hyperinsulinism can lead to significant brain injury and permanent cognitive disability. Diazoxide is the first-line and only US Food and Drug Administration\u2013approved, pharmacologic treatment for refractory hyperinsulinism. In recent years, the use of diazoxide in neonates with persistent hyperinsulinemic hypoglycemia has increased in the United States. Known adverse effects of diazoxide include fluid retention, hypertrichosis, neutropenia, thrombocytopenia, and more recently, pulmonary hypertension. It is currently unknown if diazoxide exposure is associated with an increased risk of necrotizing enterocolitis (NEC) in neonates. We reviewed the cases of 24 patients in a level IV NICU at Massachusetts General Hospital who received diazoxide over 12 years (April 2006\u2013April 2018). All 24 patients received enteral diazoxide for refractory hyperinsulinemic hypoglycemia. A total of 5 patients developed NEC after initiation of diazoxide based on clinical and radiographic findings, corresponding to 20% of infants exposed to diazoxide. This is above our baseline incidence of NEC (1% for all inborn infants and 6% for all inborn very low birth weight infants). More research and monitoring are necessary to characterize the potential risk of NEC associated with the use of diazoxide in the neonatal period.<\/jats:p>","DOI":"10.1542\/peds.2019-3202","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T10:16:37Z","timestamp":1611310597000},"source":"Crossref","is-referenced-by-count":18,"title":["Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide"],"prefix":"10.1542","volume":"147","author":[{"given":"Madeline L.","family":"Keyes","sequence":"first","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"},{"name":"Harvard Neonatal-Perinatal Medicine Fellowship Training Program, Boston, Massachusetts"},{"name":"Contributed equally as co-first authors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Healy","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"},{"name":"Harvard Neonatal-Perinatal Medicine Fellowship Training Program, Boston, Massachusetts"},{"name":"Contributed equally as co-first authors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Sparger","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas E.","family":"Orth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayya","family":"Geha","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Roumiantsev","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Matute","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Newborn Medicine, Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"12","key":"2021121021313813800_B1","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/jc.2018-01613","article-title":"Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide","volume":"103","author":"Herrera","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2021121021313813800_B2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clp.2017.10.007","article-title":"Hyperinsulinism in the neonate","volume":"45","author":"Lord","year":"2018","journal-title":"Clin Perinatol"},{"issue":"1","key":"2021121021313813800_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dme.13823","article-title":"Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia","volume":"36","author":"Banerjee","year":"2019","journal-title":"Diabetic Med"},{"key":"2021121021313813800_B4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fendo.2013.00060","article-title":"Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism","volume":"4","author":"Avatapalle","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2021121021313813800_B5","first-page":"2","article-title":"Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy","volume":"69","author":"Hussain","year":"2008","journal-title":"Horm Res"},{"issue":"2","key":"2021121021313813800_B6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4274\/jcrpe.1891","article-title":"The diagnosis and management of hyperinsulinaemic hypoglycaemia","volume":"7","author":"Ro\u017eenkov\u00e1","year":"2015","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"6","key":"2021121021313813800_B7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apa.14252","article-title":"Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects","volume":"107","author":"Balachandran","year":"2018","journal-title":"Acta Paediatr"},{"issue":"1","key":"2021121021313813800_B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.00022.2003","article-title":"Hyperinsulinism in infancy: from basic science to clinical disease","volume":"84","author":"Dunne","year":"2004","journal-title":"Physiol Rev"},{"issue":"1","key":"2021121021313813800_B9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ncpendmet0368","article-title":"Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates","volume":"3","author":"De Le\u00f3n","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"2021121021313813800_B10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"2021121021313813800_B11","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit","volume":"38","author":"Gray","year":"2018","journal-title":"J Perinatol"},{"key":"2021121021313813800_B12","volume-title":"Manual of Operations, Part 2, Release 24.0","author":"Vermont Oxford Network","year":"2020"},{"issue":"6","key":"2021121021313813800_B13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.siny.2018.07.005","article-title":"A critical analysis of risk factors for necrotizing enterocolitis","volume":"23","author":"Rose","year":"2018","journal-title":"Semin Fetal Neonatal Med"},{"issue":"2","key":"2021121021313813800_B14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","article-title":"Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children","volume":"167","author":"Thornton","year":"2015","journal-title":"J Pediatr"},{"issue":"3","key":"2021121021313813800_B15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.21037\/tp.2019.07.01","article-title":"Vermont Oxford Network: a worldwide learning community","volume":"8","author":"Edwards","year":"2019","journal-title":"Transl Pediatr"},{"key":"2021121021313813800_B16","doi-asserted-by":"crossref","first-page":"101356","DOI":"10.1016\/j.epsc.2019.101356","article-title":"Necrotizing enterocolitis following diazoxide therapy for persistent neonatal hypoglycemia","volume":"52","author":"Theodorou","year":"2020","journal-title":"J Pediatr Surg Case Rep"},{"issue":"9","key":"2021121021313813800_B17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10096-010-0965-4","article-title":"Clinical characteristics of viral intestinal infection in preterm and term neonates","volume":"29","author":"Bagci","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021121021313813800_B18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/14767058.2011.607588","article-title":"Emerging viral infections in neonatal intensive care unit","volume":"24","author":"Tzialla","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"2021121021313813800_B19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1752-1947-7-108","article-title":"Isolated colon ischemia with norovirus infection in preterm babies: a case series","volume":"7","author":"Pelizzo","year":"2013","journal-title":"J Med Case Reports"},{"issue":"3","key":"2021121021313813800_B20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jpeds.2008.04.015","article-title":"Outbreak of necrotizing enterocolitis caused by norovirus in a neonatal intensive care unit","volume":"153","author":"Turcios-Ruiz","year":"2008","journal-title":"J Pediatr"},{"issue":"3","key":"2021121021313813800_B21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10620-020-06104-w","article-title":"Necrotizing enterocolitis: a multi-omic approach and the role of the microbiome","volume":"65","author":"Neu","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2021121021313813800_B22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jpeds.2019.05.032","article-title":"Necrotizing enterocolitis: using regulatory science and drug development to improve outcomes","volume":"212","author":"Caplan","year":"2019","journal-title":"J Pediatr"},{"issue":"1","key":"2021121021313813800_B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.semperi.2016.09.013","article-title":"A critical question for NEC researchers: can we create a consensus definition of NEC that facilitates research progress?","volume":"41","author":"Gordon","year":"2017","journal-title":"Semin Perinatol"},{"issue":"2","key":"2021121021313813800_B24","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0665.1000149","article-title":"Intractable feeding intolerance and abdominal distention in a preterm infant: an unusual side effect of diazoxide","volume":"3","author":"Degirmencioglu","year":"2013","journal-title":"Pediatr Ther"},{"issue":"6","key":"2021121021313813800_B25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/nmo.12337","article-title":"Diminished vagal tone is a predictive biomarker of necrotizing enterocolitis-risk in preterm infants","volume":"26","author":"Doheny","year":"2014","journal-title":"Neurogastroenterol Motil"},{"issue":"40","key":"2021121021313813800_B26","doi-asserted-by":"crossref","first-page":"e7949","DOI":"10.1097\/MD.0000000000007949","article-title":"Late presentation of necrotizing enterocolitis associated with rotavirus infection in a term infant with hyperinsulinism on octreotide therapy: a case report","volume":"96","author":"Alsaedi","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2021121021313813800_B27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pds.4144","article-title":"Octreotide use and safety in infants with hyperinsulinism","volume":"26","author":"McMahon","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2021121021313813800_B28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-015-0367-x","article-title":"Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers","volume":"10","author":"Welters","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2021121021313813800_B29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1399-5448.2009.00547.x","article-title":"Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism","volume":"11","author":"Laje","year":"2010","journal-title":"Pediatr Diabetes"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-3202\/1082469\/peds_20193202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-3202\/1082469\/peds_20193202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T07:03:14Z","timestamp":1639206194000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/147\/2\/e20193202\/36281\/Necrotizing-Enterocolitis-in-Neonates-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-3202","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"e20193202"}}